These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32040379)

  • 1. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain.
    Ruiz-Aragón J; Gani R; Márquez S; Alvarez P
    Hum Vaccin Immunother; 2020 Sep; 16(9):2238-2244. PubMed ID: 32040379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany.
    Cai R; Gerlier L; Eichner M; Schwehm M; Rajaram S; Mould-Quevedo J; Lamotte M
    J Med Econ; 2021; 24(1):490-501. PubMed ID: 33761803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.
    Pelton SI; Mould-Quevedo JF; Nguyen VH
    Expert Rev Vaccines; 2024; 23(1):82-87. PubMed ID: 38093415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season.
    Divino V; Krishnarajah G; Pelton SI; Mould-Quevedo J; Anupindi VR; DeKoven M; Postma MJ
    Vaccine; 2020 Sep; 38(40):6334-6343. PubMed ID: 32739119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of cell-based versus egg-based quadrivalent influenza vaccines in the pediatric population in Taiwan.
    Chi CY; Cheng MF; Ko K; Mould JF; Chen CJ; Huang YC; Lee PI
    J Med Virol; 2024 Jan; 96(1):e29279. PubMed ID: 38196182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina.
    Urueña A; Micone P; Magneres MC; McGovern I; Mould-Quevedo J; Sarmento TTR; Giglio N
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada.
    Nguyen VH; Roy B
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
    Jamotte A; Chong CF; Manton A; Macabeo B; Toumi M
    BMC Public Health; 2016 Jul; 16():630. PubMed ID: 27449665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
    Crépey P; Redondo E; Díez-Domingo J; Ortiz de Lejarazu R; Martinón-Torres F; Gil de Miguel Á; López-Belmonte JL; Alvarez FP; Bricout H; Solozabal M
    PLoS One; 2020; 15(5):e0233526. PubMed ID: 32437476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial.
    Essink BJ; Heeringa M; Jeanfreau RJ; Finn D; Matassa V; Edelman J; Hohenboken M; Molrine D
    Pediatrics; 2022 Nov; 150(5):. PubMed ID: 36214072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach.
    Nguyen VH; Hilsky Y; Mould-Quevedo J
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
    Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States.
    Krishnarajah G; Divino V; Postma MJ; Pelton SI; Anupindi VR; DeKoven M; Mould-Quevedo J
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33498724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review.
    Mould-Quevedo JF; Pelton SI; Nguyen VH
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37896996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain.
    Ruiz-Aragón J; Márquez-Peláez S; Gani R; Alvarez P; Guerrero-Luduena R
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation studies to assess the long-term effects of Japan's change from trivalent to quadrivalent influenza vaccination.
    Tsuzuki S; Schwehm M; Eichner M
    Vaccine; 2018 Jan; 36(5):624-630. PubMed ID: 29292176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
    Yang MC; Tan EC; Su JJ
    Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of a quadrivalent influenza vaccine in Italy: a budget impact analysis.
    Pitrelli A
    J Prev Med Hyg; 2016; 57(1):E34-40. PubMed ID: 27346938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.